PARP1 and glioblastoma: Although the strong PARP trapper talazoparib has shown to sensitize GBM cell lines and orthotropic GBM models to TMZ, it has demonstrated a restricted ability to cross the BBB.44 A phase II trial of talazoparib is currently recruiting recurrent high-grade glioma patients with DDR deficiency to investigate if combining carboplatin and radiation may sensitize tumors to PARP inhibition and increase talazoparib drug penetration across the BBB (NCT04740190).